Prenatal CFTR Modulator Therapy for Fetal CF: A Promising but Still Investigational Frontier

Hiba J Mustafa, Yair J Blumenfeld, Ramen H Chmait, et al.

Summary: This review synthesizes current evidence on prenatal exposure to CFTR modulator therapies — primarily elexacaftor/tezacaftor/ivacaftor (ETI) and the newer vanzacaftor/tezacaftor/deutivacaftor (VTD) — in pregnancies affected by cystic fibrosis, both for maternal benefit and as a potential directed fetal therapy. Key findings include placental transfer of both agents at pharmacologically relevant fetal concentrations, apparent stabilization of maternal pulmonary and nutritional status, and case-series evidence of resolution or improvement of fetal bowel abnormalities consistent with meconium ileus. The review also highlights unresolved questions around timing, fetal pharmacokinetics, long-term neurodevelopmental outcomes, and the risk of falsely negative newborn screening.

Why it matters: CF organ damage begins in utero — meconium ileus, pancreatic insufficiency, and reproductive tract anomalies are present at birth — so the prospect of a first true fetal therapy for CF is scientifically and clinically significant. The transformation of CF prognosis by modulators has also produced a substantial increase in pregnancies among people with CF, making the maternal-continuation question immediately practical for large numbers of clinicians and patients. If intentional prenatal therapy can reliably prevent meconium ileus and preserve pancreatic or reproductive function, the implications for morbidity and quality of life would be meaningful, though this remains to be established rigorously.

Expert perspective: The evidence base here is genuinely early-stage and must be read accordingly. The body of data consists of observational cohorts, case series, pharmacokinetic studies, animal models, and expert consensus — not randomized controlled trials, which are difficult to design and execute in pregnancy. Selection bias is a substantial concern: women continuing ETI during pregnancy are likely to be healthier and more closely monitored than those who discontinue, and individual fetal cases reported in series are unlikely to be representative. The cataract signal, though described as clinically minor so far, has not been systematically evaluated across large cohorts, and the mechanism is not fully understood; it warrants continued structured surveillance. The newborn screening problem — falsely negative results following prenatal modulator exposure — is an immediately actionable, underappreciated public-health issue that deserves explicit clinical protocols now, regardless of broader questions about fetal indication. The authors are appropriately cautious in labeling fetal-indication use as investigational, and the call for interdisciplinary coordination and the PROTECT Workshop framework reflects a responsible approach. The field needs prospective registries with standardized outcome definitions, long-term neurodevelopmental follow-up, and ideally some form of controlled comparative design, even if conventional randomization is not feasible. The gap between the biological rationale and the evidence needed to guide routine fetal-indication prescribing remains wide.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42819752/

---